Overview

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company